Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection

This phase 3, open-label, single-arm trial assesses the safety of SER-109 and the rate of recurrent Clostridioides difficile infection after administration of SER-109 following symptom resolution after antibiotic treatment among adults.

[1]  J. Auniņš,et al.  Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool , 2022, Open forum infectious diseases.

[2]  W. Nelson,et al.  Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. , 2022, Journal of the American Medical Directors Association.

[3]  J. Wortman,et al.  SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. , 2022, The New England journal of medicine.

[4]  Karalyn Pappas,et al.  Health care consequences of hospitalization with Clostrioides difficile infection: a propensity score matching study , 2021, BMC Infectious Diseases.

[5]  D. Pardi,et al.  Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection , 2021, Expert review of anti-infective therapy.

[6]  K. Garey,et al.  Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  C. Kelly,et al.  ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections , 2021, The American journal of gastroenterology.

[8]  G. Dantas,et al.  Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients , 2021, mSphere.

[9]  V. Young.  Unexpected Results from a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Wortman,et al.  SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Jeffrey P. Ferraro,et al.  Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection , 2020, Antimicrobial Agents and Chemotherapy.

[12]  D. Gerding,et al.  Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection with Greater Severity and Higher Recurrence Rates. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Gasbarrini,et al.  What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases , 2019, Microorganisms.

[14]  Xuemei Wang,et al.  Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients , 2019, European journal of gastroenterology & hepatology.

[15]  D. Gerding,et al.  Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Snydman,et al.  Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin , 2018, PloS one.

[17]  D. Gerding,et al.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  L. Baddour,et al.  The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease , 2017, Scandinavian journal of gastroenterology.

[19]  E. Dubberke,et al.  Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results , 2016, Journal of Clinical Microbiology.

[20]  S. Allen,et al.  National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals , 2016, BMC Infectious Diseases.

[21]  V. Young,et al.  Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection , 2016, Genome Medicine.

[22]  Sean M. Kearney,et al.  Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles , 2016, Alimentary pharmacology & therapeutics.

[23]  V. Young,et al.  Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine , 2016, mSphere.

[24]  Henry E. Wang,et al.  Hospital‐Onset Clostridium difficile Infection Among Solid Organ Transplant Recipients , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  V. Young,et al.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. , 2015, Annual review of microbiology.

[26]  C. Kelly,et al.  Recurrent Clostridium difficile infection: From colonization to cure. , 2015, Anaerobe.

[27]  C. Donskey,et al.  Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis , 2015, Infection Control & Hospital Epidemiology.

[28]  D. Paterson,et al.  Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: A Systematic Review and Meta-analysis , 2014, Infection Control & Hospital Epidemiology.

[29]  R. Knight,et al.  What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat Clostridium difficile Infection? , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  C. Donskey,et al.  Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole , 2013, PloS one.

[31]  D. Gerding,et al.  Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. , 2013, JAMA internal medicine.

[32]  Sang-Uk Seo,et al.  Role of the gut microbiota in immunity and inflammatory disease , 2013, Nature Reviews Immunology.

[33]  T. Louie,et al.  Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Derrick W. Crook,et al.  Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Michael P. Anderson,et al.  Clostridium difficile Infection Is Associated With Poor Outcomes in End-Stage Renal Disease , 2012, Journal of Investigative Medicine.

[36]  M. Wilcox.  Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[37]  C. Kelly.  Can we identify patients at high risk of recurrent Clostridium difficile infection? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  V. Debari,et al.  Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. , 2011, American journal of infection control.

[39]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[40]  Carlene A. Muto,et al.  Antimicrobial-associated risk factors for Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.